Literature DB >> 18428667

Overview of animal models of schizophrenia.

Susan B Powell1, Mark A Geyer.   

Abstract

Animal models of schizophrenia may increase the understanding of the neurological abnormalities associated with the disorder and aid in the development of rational pharmacological treatments. Rather than attempting to model the entire syndrome of schizophrenia, a more biologically oriented approach to animal models has been to focus on specific symptoms of schizophrenia that are more objectively measured in the clinical population and more directly translatable to animals (e.g., observables or endophenotypes). This overview focuses on behavioral measures that have been investigated in rodent models of schizophrenia with varying degrees of predictive, etiological, and construct validity. Because of the severity of cognitive deficits in schizophrenia and their resistance to current treatments, there is a need to develop animal models specific to the cognitive symptoms of schizophrenia. In light of this need, this overview discusses rodent models of cognition with relevance to the core cognitive deficits observed in schizophrenia.

Entities:  

Mesh:

Year:  2007        PMID: 18428667     DOI: 10.1002/0471142301.ns0924s39

Source DB:  PubMed          Journal:  Curr Protoc Neurosci        ISSN: 1934-8576


  12 in total

1.  Antipsychotic-Like Efficacy of Dopamine D2 Receptor-Biased Ligands is Dependent on Adenosine A2A Receptor Expression.

Authors:  Kristoffer Sahlholm; Maricel Gómez-Soler; Marta Valle-León; Marc López-Cano; Jaume J Taura; Francisco Ciruela; Víctor Fernández-Dueñas
Journal:  Mol Neurobiol       Date:  2017-08-05       Impact factor: 5.590

Review 2.  Integrated approaches to understanding antipsychotic drug action at GPCRs.

Authors:  Nikhil M Urs; Peter J Nicholls; Marc G Caron
Journal:  Curr Opin Cell Biol       Date:  2013-12-14       Impact factor: 8.382

Review 3.  A role for Akt and glycogen synthase kinase-3 as integrators of dopamine and serotonin neurotransmission in mental health.

Authors:  Jean-Martin Beaulieu
Journal:  J Psychiatry Neurosci       Date:  2012-01       Impact factor: 6.186

Review 4.  Models of neurodevelopmental abnormalities in schizophrenia.

Authors:  Susan B Powell
Journal:  Curr Top Behav Neurosci       Date:  2010

Review 5.  Preclinical models of antipsychotic drug action.

Authors:  José L Moreno; Javier González-Maeso
Journal:  Int J Neuropsychopharmacol       Date:  2013-06-10       Impact factor: 5.176

6.  Distinct cortical and striatal actions of a β-arrestin-biased dopamine D2 receptor ligand reveal unique antipsychotic-like properties.

Authors:  Nikhil M Urs; Steven M Gee; Thomas F Pack; John D McCorvy; Tama Evron; Joshua C Snyder; Xiaobao Yang; Ramona M Rodriguiz; Emiliana Borrelli; William C Wetsel; Jian Jin; Bryan L Roth; Patricio O'Donnell; Marc G Caron
Journal:  Proc Natl Acad Sci U S A       Date:  2016-12-01       Impact factor: 11.205

Review 7.  Animal models of serotonergic psychedelics.

Authors:  James B Hanks; Javier González-Maeso
Journal:  ACS Chem Neurosci       Date:  2012-09-24       Impact factor: 4.418

Review 8.  Group II metabotropic glutamate receptors and schizophrenia.

Authors:  José L Moreno; Stuart C Sealfon; Javier González-Maeso
Journal:  Cell Mol Life Sci       Date:  2009-08-26       Impact factor: 9.261

Review 9.  Serotonergic hallucinogens as translational models relevant to schizophrenia.

Authors:  Adam L Halberstadt; Mark A Geyer
Journal:  Int J Neuropsychopharmacol       Date:  2013-08-13       Impact factor: 5.176

10.  Global quantitative analysis of phosphorylation underlying phencyclidine signaling and sensorimotor gating in the prefrontal cortex.

Authors:  D B McClatchy; J N Savas; S Martínez-Bartolomé; S K Park; P Maher; S B Powell; J R Yates
Journal:  Mol Psychiatry       Date:  2015-04-14       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.